PDF herunterladen
Journal of Pediatric Neurology 2021; 19(06): 423-424
DOI: 10.1055/s-0040-1718771
Case Report

Fluctuating Weakness in an 18-Month-Boy: Congenital Myasthenia

Arundhati Banerjee
1   Department of Pediatrics, Pediatric Neurology Unit, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India
,
Gananamani Senguttuvan
1   Department of Pediatrics, Pediatric Neurology Unit, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India
,
Chaitanya Reddy
1   Department of Pediatrics, Pediatric Neurology Unit, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India
,
Arushi Gahlot Saini 
1   Department of Pediatrics, Pediatric Neurology Unit, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India
› Institutsangaben Funding None.
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

In this article, we reported a case of an 18-month-old male child patient who presented with motor predominant delay in attaining developmental milestones and early onset fatiguable weakness with ptosis and ophthalmoparesis. This ptosis and ophthalmoparesis typically worsened with progression of the day. Examination showed proximal weakness with preserved muscle stretch reflexes. Electrophysiology showed characteristic decrement on repetitive nerve stimulation test that localized to disorders of the neuromuscular junction. Next-generation sequencing showed a pathogenic variant of CHRNE that was responsible for congenital myasthenic syndrome. Such variants show increased improvement with salbutamol in addition to anticholinesterase inhibitors. Hence, the patient was started on pyridostigmine, and the plan was to add on salbutamol on follow-up if optimal improvement does not occur.

Keywords

ptosis - diurnal variation - ophthalmoparesis - pyridostigmine - salbutamol


Publikationsverlauf

Eingereicht: 27. Juni 2020

Angenommen: 22. September 2020

Artikel online veröffentlicht:
03. November 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Engel AG, Shen XM, Selcen D, Sine SM. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol 2015; 14 (04) 420-434
    CrossrefPubMedGoogle Scholar
  • 2 Shen X-M, Crawford TO, Brengman J. et al. Functional consequences and structural interpretation of mutations of human choline acetyltransferase. Hum Mutat 2011; 32 (11) 1259-1267
    CrossrefPubMedGoogle Scholar
  • 3 Shen XM, Selcen D, Brengman J, Engel AG. Mutant SNAP25B causes myasthenia, cortical hyperexcitability, ataxia, and intellectual disability. Neurology 2014; 83 (24) 2247-2255
    CrossrefPubMedGoogle Scholar
  • 4 Liewluck T, Selcen D, Engel AG. Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia. Muscle Nerve 2011; 44 (05) 789-794
    CrossrefPubMedGoogle Scholar
  • 5 Padmanabha H, Saini AG, Sankhyan N, Singhi P. COLQ-related congenital myasthenic syndrome and response to salbutamol therapy. J Clin Neuromuscul Dis 2017; 18 (03) 162-163
    CrossrefPubMedGoogle Scholar
  • 6 Ohno K, Quiram PA, Milone M. et al. Congenital myasthenic syndromes due to heteroallelic nonsense/missense mutations in the acetylcholine receptor ε subunit gene: identification and functional characterization of six new mutations. Hum Mol Genet 1997; 6 (05) 753-766
    CrossrefPubMedGoogle Scholar
  • 7 Kinali M, Beeson D, Pitt MC. et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. J Neuroimmunol 2008; 201-202: 6-12
    CrossrefPubMedGoogle Scholar
  • 8 Burke G, Cossins J, Maxwell S. et al. Distinct phenotypes of congenital acetylcholine receptor deficiency. Neuromuscul Disord 2004; 14 (06) 356-364
    CrossrefPubMedGoogle Scholar